CY1114198T1 - Συμπλοκα εγκλεισμου που περιεχουν πιροξικαμη, μια κυκλοδεξτρινη και αργινινη - Google Patents

Συμπλοκα εγκλεισμου που περιεχουν πιροξικαμη, μια κυκλοδεξτρινη και αργινινη

Info

Publication number
CY1114198T1
CY1114198T1 CY20131100671T CY131100671T CY1114198T1 CY 1114198 T1 CY1114198 T1 CY 1114198T1 CY 20131100671 T CY20131100671 T CY 20131100671T CY 131100671 T CY131100671 T CY 131100671T CY 1114198 T1 CY1114198 T1 CY 1114198T1
Authority
CY
Cyprus
Prior art keywords
arginine
cyclodexine
closing
complexes containing
piroxicam
Prior art date
Application number
CY20131100671T
Other languages
English (en)
Inventor
Bernard Freiss
Florence Marciacq
Hubert Lochard
Original Assignee
Pierre Fabre Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0403450A external-priority patent/FR2868315B1/fr
Priority claimed from FR0411201A external-priority patent/FR2876911B1/fr
Application filed by Pierre Fabre Medicament filed Critical Pierre Fabre Medicament
Publication of CY1114198T1 publication Critical patent/CY1114198T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ένα σύμπλοκο που περιλαμβάνει πιροξικάμη, μία κυκλοδεξτρίνη και αργινίνη που χαρακτηρίζεται από το ότι το ποσοστό διαλυτοποίησης της πιροξικάμης που περιέχεται σε ένα διάλυμα 4 γραμ./ λ σε ύδωρ, που μετράται στους 37°C, μετά ανάδευση περίπου 5 και 120 λεπτών είναι μεγαλύτερο του 90%, πλεονεκτικά ανώτερο του 95%, κατά πλεονεκτικό τρόπο ανώτερο του 99%.
CY20131100671T 2004-04-01 2013-08-07 Συμπλοκα εγκλεισμου που περιεχουν πιροξικαμη, μια κυκλοδεξτρινη και αργινινη CY1114198T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0403450A FR2868315B1 (fr) 2004-04-01 2004-04-01 Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique
FR0411201A FR2876911B1 (fr) 2004-10-21 2004-10-21 Complexe comprenant du piroxicam, une cyclodextrine et de l'arginine
EP10182089.2A EP2260871B1 (fr) 2004-04-01 2005-03-29 Complexes d'inclusions comprenant du piroxicam, une cyclodextrine et l'arginine

Publications (1)

Publication Number Publication Date
CY1114198T1 true CY1114198T1 (el) 2016-08-31

Family

ID=34968371

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100671T CY1114198T1 (el) 2004-04-01 2013-08-07 Συμπλοκα εγκλεισμου που περιεχουν πιροξικαμη, μια κυκλοδεξτρινη και αργινινη

Country Status (16)

Country Link
US (2) US8461133B2 (el)
EP (2) EP1729813B1 (el)
JP (1) JP5091661B2 (el)
AR (1) AR049488A1 (el)
AT (1) ATE504316T1 (el)
BR (1) BRPI0509482B1 (el)
CA (1) CA2563101C (el)
CY (1) CY1114198T1 (el)
DE (1) DE602005027333D1 (el)
DK (1) DK2260871T3 (el)
ES (1) ES2424235T3 (el)
PL (2) PL1729813T3 (el)
PT (2) PT1729813E (el)
RU (1) RU2382654C2 (el)
SI (1) SI2260871T1 (el)
WO (1) WO2005097201A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2876914A1 (fr) * 2004-10-21 2006-04-28 Pierre Fabre Medicament Sa Complexe comprenant un antibiotique, une cyclodextrine et un agent d'interaction
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
FR2914187B1 (fr) * 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
KR101383941B1 (ko) 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CN109142420B (zh) * 2018-10-12 2020-01-10 厦门大学 基于核磁共振技术探究药物在胶束内最大增溶量的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434163A (en) 1981-06-01 1984-02-28 Pfizer Inc. Water-soluble benzothiazine dioxide salts
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
JPS632929A (ja) * 1986-06-20 1988-01-07 Kao Corp アセチルサリチル酸製剤
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
KR920006911B1 (ko) * 1989-06-14 1992-08-22 신풍제약 주식회사 안정한 피록시캄 주사액 조성물 및 그의 제조방법
IT1241088B (it) 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
WO1992003048A1 (en) * 1990-08-13 1992-03-05 Commonwealth Scientific And Industrial Research Organisation Pesticidal products
EP1004318A3 (en) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Cyclodextrin composition
AT400674B (de) 1991-07-24 1996-02-26 Biochemie Gmbh Pharmazeutische pleuromutilin-zubereitung
IT1293764B1 (it) 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
ES2149750T3 (es) 1999-01-06 2004-06-01 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Complejos de inclusion de sales de aminoacidos de derivados de bencimidazol con ciclodextrinas, su preparacion y formulaciones farmaceuticas que contienen tales complejos.
FR2815540B1 (fr) 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
WO2002089851A1 (fr) * 2001-03-06 2002-11-14 Separex (Societe Anonyme) Procede de fabrication de complexes hote-client
FR2830760B1 (fr) * 2001-10-12 2004-06-04 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique
FR2830761B1 (fr) 2001-10-12 2003-12-12 Pf Medicament Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique
RU2004123612A (ru) * 2002-01-15 2005-04-20 ЮСиБи ФАРШИМ С.А. (CH) Фармацевтическая композиция для перорального применения
ATE359827T1 (de) * 2002-06-17 2007-05-15 Chiesi Farma Spa Prozess für die vorbereitung von piroxicam: beta- cyclodextrin einschlusskomplexe
FR2854079B1 (fr) * 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
WO2005112637A1 (en) * 2004-05-14 2005-12-01 Decode Chemistry, Inc. Formulations for non-parenteral use including hydrophobic cyclodextrins

Also Published As

Publication number Publication date
WO2005097201A2 (fr) 2005-10-20
PT1729813E (pt) 2011-07-12
PL1729813T3 (pl) 2011-09-30
EP2260871B1 (fr) 2013-05-15
EP2260871A3 (fr) 2011-05-18
EP2260871A2 (fr) 2010-12-15
JP5091661B2 (ja) 2012-12-05
RU2006138488A (ru) 2008-05-10
BRPI0509482A (pt) 2007-09-11
CA2563101C (fr) 2013-07-02
BRPI0509482B1 (pt) 2018-12-11
WO2005097201A3 (fr) 2006-08-17
EP1729813A2 (fr) 2006-12-13
PL2260871T3 (pl) 2013-10-31
ATE504316T1 (de) 2011-04-15
EP1729813B1 (fr) 2011-04-06
ES2424235T3 (es) 2013-09-30
SI2260871T1 (sl) 2013-09-30
US20070270379A1 (en) 2007-11-22
AR049488A1 (es) 2006-08-09
PT2260871E (pt) 2013-08-01
DK2260871T3 (da) 2013-08-26
US8461133B2 (en) 2013-06-11
US9243076B2 (en) 2016-01-26
CA2563101A1 (fr) 2005-10-20
US20130316975A1 (en) 2013-11-28
DE602005027333D1 (de) 2011-05-19
RU2382654C2 (ru) 2010-02-27
JP2007530641A (ja) 2007-11-01

Similar Documents

Publication Publication Date Title
CY1114198T1 (el) Συμπλοκα εγκλεισμου που περιεχουν πιροξικαμη, μια κυκλοδεξτρινη και αργινινη
CY1113069T1 (el) Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
NO20035301D0 (no) Små molekyl¶re antagonister av proteiner i BCL-2-familien
MX2009004677A (es) Polimeros dispersables de poligalactomanano tratados con quelatos o sales de metal sin borato para su uso en aplicaciones para el cuidado personal y cuidado del hogar.
CY1112798T1 (el) Ενωσεις διαρυλυδαντοϊνης
ATE534377T1 (de) Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
RS53318B (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
CY1115078T1 (el) Παραγωγα πυραζολοαμινοπυριδινης χρησιμα ως αναστολεις της κινασης
BRPI0710485B1 (pt) composições líquidas úteis no tratamento de doenças respiratórias
NO20074941L (no) Anvendelse av diosmetinforbindelser i behandlingen og forebyggingen av trombotiske patologier
DE60333557D1 (de) Nasse tücher enthaltend komplex zur verlängerten duftstofffreisetzung
EA201290062A1 (ru) Соединения, связывающие белки теплового шока, композиции и способы получения указанных соединений
TR201909741T4 (tr) Kolon temizleme bileşimleri.
EA200701634A1 (ru) Добавки к средствам для мытья тела
EA200870594A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
CY1110967T1 (el) Απεικονιση, διαγνωση και θεραπεια ασθενειας
RU2006116252A (ru) Водные композиции, содержащие метронидазол
CY1106508T1 (el) Συνδυασμος αναστολεα κυκλοοξυγενασης-2/αναστολεα αποακετυλασης της ιστονης
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
ATE304866T1 (de) Chelatorkonjugate mit verbesserten eigenschaften
NO20055741D0 (no) Nye kjemiske forbindelser
DE60134274D1 (en) Complex enthaltend modafinil und cyclodextrin
CY1114930T1 (el) Συνθεση που περιλαμβανει συστατικα γαστρολιθου καρκινοειδων, ανθρακικο ασβεστιο και η χρηση της
ATE413176T1 (de) Verwendung von 1-azabicyclo(2.2.2)octan-3-on- derivaten zur behandlung von krebstumoren
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut